Published in Women's Health Weekly, August 30th, 2001
Ovarian cancer claims more lives in the U.S. than any other gynecologic malignancy, in part because there is currently no reliable diagnostic tool. The primary objective of the trial is to use Atairgin's lipid assay to confirm the presence of an ovarian malignancy in women with a suspicious pelvic mass. Atairgin expects to complete the sample testing and statistical analysis phases of the trial in the third quarter of 2001 and intends to submit the PMA (premarket...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.